Skip to Main Content

WASHINGTON — It has all the makings of a bombastic drug pricing debate: a highly anticipated drug, widespread press attention, a huge potential patient population, and a price higher than even some of the highest Wall Street estimates.

But when Biogen announced Monday it would charge $56,000 for an annual course of its just-approved Alzheimer’s treatment, the activists who are normally eager to criticize pharma and its pricing strategies were largely silent. So, too, were progressives on Capitol Hill, many of whom have decried high drug prices as a key campaign issue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • If it’s as useful as Aricept, the Country has been sold a real lemon. For now, what is needed in Dementia is a nutricuetical type placebo with questionable to no efficacy. Think B12. At least that wouldn’t break the bank.

Comments are closed.